Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Idalopirdine Formulations in Healthy Subjects
NCT02371707Phase 1Completed
- Sponsor
- Lundbeck
- Start
- Mar 2015
- Primary completion
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Idalopirdine in Alzheimer's disease (AD) (2 arms), sponsored by Lundbeck. Primary endpoints: Area under the plasma concentration-time curve and Maximum observed concentration. Started Mar 2015; status: completed.
02
Drugs
Idalopirdine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02371707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02371707.